drugset / Trial / NCT02280473

A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease

NCT02280473

Phase 3 Completed 188 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy o fRefresh Optive® Gel Drops in patients with dry eye disease.

Timeline

Start
2014-11-13
Primary completion
2015-03-16
Completion
2015-03-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Refresh Optive® Gel Drops Unknown Other
Comparator sodium chloride Unknown Other

Indications